关于单克隆抗体临床药理学的一段翻译

2008-10-05 09:53 阅读(?)评论(0)

Monoclonal antibodies (Mabs) are proteins in the immunoglobulin family that bind to specific protein epitope targets on cancer and stromal cells, allowing them to be successfully exploited as therapeutic agents. The prototype Mabs were produced from fusion of mouse B lymphocytes and mouse myeloma cells and were entirely murine in sequence. Subsequent advances in technology have allowed for humanized Mabs, which have different pharmacokinetic properties than murine Mabs in humans. Mabs antitumour activity is mediated through direct interaction with specific target molecules, deployment of immune cytotoxic pathways, or through chaperoning cytotoxic agents to tumour. Mabs are typically administered intravenously, are generally well tolerated and can have powerful anticancer activity. Humanized Mabs have a t1/2 in human sera of 2–3 weeks, which determines the frequency of administration. At present, nine clinically approved Mabs are used in the treatment of human cancer, and many others are in clinical trials. We discuss the pharmacology, clinical indications, and toxicity of the currently available anticancer Mabs in this review.

单克隆抗体是免疫球蛋白家族中的一种蛋白质,它在癌细胞和基质细胞上与特定的蛋白质表位靶连接,使它们可以被成功地开发利用为治疗药物。单克隆抗体的原型是由老鼠的B淋巴细胞和骨髓瘤细胞融合而生成的,在序列上是完全鼠源的。后来技术的发展使人源化单克隆抗体成为可能,它和鼠源单克隆抗体的药代动力学属性不同。单克隆抗体的抗肿瘤活性是通过直接和特定的靶分子相互作用,免疫细胞毒素途径的部署,或者通过对肿瘤的陪伴性细胞毒素剂等进行调节的。单克隆抗体通常是通过静脉途径给药,通常具有良好的耐受性和强大的抗肿瘤活性。人源单克隆抗体在人类血浆中的半衰期约为2-3周,这决定了用药频率。目前,已有九种临床批准的单克隆抗体用于治疗人类的癌症,另外还有很多单克隆抗体已进入临床试验阶段。在本评论文章中我们来讨论当前已有的抗癌单克隆抗体的药理学、临床应用及其毒理学。

专业术语
monoclonal antibody 单克隆抗体
immunoglobulin 免疫球蛋白
epitope 抗原决定部位,抗原决定基(抗原分子中决定抗原特异性的特殊化学基团称抗原决定基,又称表位)
lymphocyte 淋巴细胞,淋巴球
myeloma cell 骨髓瘤细胞
murine 鼠科的;鼠科动物(传播的)
pharmacokinetic 药代动力学的
antitumour activity 抗肿瘤活性
administer 给药,用药
well tolerated 耐受良好的,有良好耐性的
indication 适应征





 
表  情:
加载中...
 

请各位遵纪守法并注意语言文明